Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (1)

Search Parameters:
Keywords = the non-target embolization (NTE)

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
9 pages, 632 KB  
Article
Performance and Safety of a Reflux-Control Microcatheter Used to Perform DEB-TACE with LUMITM Beads in HCC Patients: Preliminary Experience
by Salvatore Alessio Angileri, Carolina Lanza, Serena Carriero, Pierpaolo Biondetti, Velio Ascenti, Giuseppe Pellegrino, Alessandro Caruso, Gianpaolo Carrafiello and Anna Maria Ierardi
J. Clin. Med. 2023, 12(20), 6630; https://doi.org/10.3390/jcm12206630 - 19 Oct 2023
Cited by 1 | Viewed by 2270
Abstract
Purpose: The present study aims to evaluate the effectiveness and safety of the anti-reflux microcatheter during DEB-TACE with DC Bead LUMITM (radiopaque beads) for the treatment of hepatocellular carcinoma (HCC). Methods: We performed an observational longitudinal prospective monocentric study to analyze all [...] Read more.
Purpose: The present study aims to evaluate the effectiveness and safety of the anti-reflux microcatheter during DEB-TACE with DC Bead LUMITM (radiopaque beads) for the treatment of hepatocellular carcinoma (HCC). Methods: We performed an observational longitudinal prospective monocentric study to analyze all patients with HCC who underwent to DEB-TACE with DC Bead LUMITM and anti-reflux microcatheter. Technical success, the presence of residual disease, and clinical success were evaluated. The performance of the anti-reflux microcatheter on the basis of the percentage of tumor covered and the non-target embolization (NTE) was also evaluated. Results: Twenty patients underwent DEB-TACE with DC Bead LUMITM and an anti-reflux microcatheter. Technical success was achieved in all cases. Residual disease in the target tumor was observed in 11/20 (55%) of cases and no residual disease was found in 9/20 (45%) of cases. The clinical response at 1-month follow-up was of PD 4/20 (20%), SD 7/20 (35%), and CR 9/20 (45%). No major complications were recorded, and 10% of cases had minor complications. The distribution of beads on post-procedural CBCT, classified according to the percentage of target nodule coverage, was ≥50% in 70% (14/20) of cases and between 30–50% in 30% of cases (6/20). NTE was never registered. Full article
Show Figures

Figure 1

Back to TopTop